Ironwood Pharmaceuticals reported $29.83M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 10.34M 441K Dec/2025
Almirall EUR 191.5M 2.29M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
Ardelyx USD 10.85M 6.87M Dec/2025
Astellas Pharma JPY 149.13B 10.88B Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Charles River Laboratories USD 722.27M 28.81M Dec/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Exact Sciences USD 266.81M 18.18M Sep/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Moderna USD 452M 245M Dec/2025
Myriad Genetics USD 63M 1.1M Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024